XML 153 R83.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended
May 14, 2021
May 01, 2021
Jul. 31, 2021
Jun. 30, 2021
May 31, 2021
Mar. 31, 2021
Mar. 31, 2020
May 31, 2019
Debt principal amount           $ 20,000   $ 20,000
Interest rate   10.00%            
Maturity date   5 years            
Warrants exercise price         $ 0.01      
Long term debt       $ 186,350   170,280 $ 108,592  
Subscription receivable       $ 100,000   100,000 $ 0  
Dermavant Sciences Ltd [Member] | Subsequent Event [Member]                
Warrants issued to purchase common shares 1,199,072              
Warrants exercise price $ 0.01              
Dermavant Sciences Ltd [Member] | Subsequent Event [Member] | Credit Facility [Member]                
Debt principal amount $ 40,000              
Interest rate 10.00%              
Maturity date 5 years              
Dermavant Sciences Ltd [Member] | Subsequent Event [Member] | Revenue Interest Purchase and Sale Agreement [Member]                
Revenue interest purchase and sale agreement amount $ 160,000              
Revenue interest purchase and sale agreement committed fund to be paid $ 160,000              
Dermavant Sciences Ltd [Member] | Subsequent Event [Member] | Revision of Prior Period, Reclassification, Adjustment                
Long term debt           $ 3,100    
Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. [Member] | Subsequent Event [Member]                
Business combination, paid in cash   $ 5,000            
ProteoVant Sciences, Inc [Member] | Subsequent Event [Member]                
Subscription receivable     $ 100,000          
Equity Method Investments     $ 200,000          
Equity Method Investment, Ownership Percentage     40.00%          
Datavant [Member] | Subsequent Event [Member]                
Business combination, consideration transferred     $ 320,000